SKAP2, a Candidate Gene for Type 1 Diabetes, Regulates β-Cell Apoptosis and Glycemic Control in Newly Diagnosed Patients

Tina Fløjel,1 Kira Meyerovich,2 Michala C. Prause,1,3 Simranjeet Kaur,3 Caroline Frørup,1 Henrik B. Mortensen,4,5 Lotte B. Nielsen,4 Flemming Pociot,1,5 Alessandra K. Cardozo,2 and Joachim Størling1,3

Diabetes 2021;70:464–476 | https://doi.org/10.2337/db20-0092

The single nucleotide polymorphism rs7804356 located in the Src kinase-associated phosphoprotein 2 (SKAP2) gene is associated with type 1 diabetes (T1D), suggesting SKAP2 as a causal candidate gene. The objective of the study was to investigate if SKAP2 has a functional role in the β-cells in relation to T1D. In a cohort of children with newly diagnosed T1D, rs7804356 predicted glycemic control and residual β-cell function during the 1st year after diagnosis. In INS-1E cells and rat and human islets, proinflammatory cytokines reduced the content of SKAP2. Functional studies revealed that knockdown of SKAP2 aggravated cytokine-induced apoptosis in INS-1E cells and primary rat β-cells, suggesting an antiapoptotic function of SKAP2. In support of this, overexpression of SKAP2 afforded protection against cytokine-induced apoptosis, which correlated with reduced nuclear content of S536-phosphorylated nuclear factor-κB (NF-κB) subunit p65, lower nitric oxide production, and diminished CHOP expression indicative of decreased endoplasmic reticulum stress. Knockdown of CHOP partially counteracted the increase in cytokine-induced apoptosis caused by SKAP2 knockdown. In conclusion, our results suggest that SKAP2 controls β-cell sensitivity to cytokines possibly by affecting the NF-κB–inducible nitric oxide synthase–endoplasmic reticulum stress pathway.

Type 1 diabetes (T1D) is a chronic immune-mediated disease in which the pancreatic β-cells are destroyed. In this process, proinflammatory cytokines such as interleukin-1β (IL-1β) and interferon-γ (IFN-γ) contribute to T1D by causing β-cell apoptosis (1,2). A strong genetic component is present in T1D, with >60 risk loci identified (3–6). These loci contain numerous disease candidate genes, some of which have been shown to have functional roles in pancreatic β-cells, such as regulation of apoptotic cell death in response to cytokines (7–14).

Src kinase-associated phosphoprotein 2 (SKAP2) is located on chromosome 7p15.2 and harbors a single nucleotide polymorphism (SNP), rs7804356, in the third intron of SKAP2, which associates with T1D (5,15). Recently, a study found that the risk allele of this SNP correlates with lower SKAP2 expression in Epstein-Barr virus–transformed B-lymphocyte lines as well as in CD4+ and CD8+ T cells (16), indicating that rs7804356 may affect T1D risk by regulating the SKAP2 expression level.

SKAP2, which is also known as SKAP-HOM, is ubiquitously expressed and was initially identified in lymphocytes as a cytosolic adaptor protein and an Src kinase substrate (17,18). Loss-of-function studies revealed that SKAP2 is dispensable for T-lymphocyte activation in response to various stimuli but required for B-lymphocyte proliferative responses and adhesion induced by anti-IgM or lipopolysaccharide (19). In macrophage precursor cells, SKAP2 associates with actin and is involved in proliferation, migration, and chemotaxis (20,21). The function of SKAP2 in β-cells is currently unknown, but we recently

1Translational Type 1 Diabetes Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark
2ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium
3Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
4Department of Pediatrics E, Herlev and Gentofte Hospital, Herlev, Denmark
5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Corresponding author: Joachim Størling, joachim.stoerling@regionh.dk
Received 29 January 2020 and accepted 10 November 2020
This article contains supplementary material online at https://doi.org/10.2337/figshare.13217447.
© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
reported that cytokines decrease the mRNA expression of SKAP2 in human pancreatic islets (22), suggesting that SKAP2 could play a functional role in β-cells for cytokine-mediated impairment. In this study, we show that rs7804356 in SKAP2 can predict residual β-cell function and glycemic control in the 1st year after diagnosis in a cohort of children with newly diagnosed T1D. Further, we provide evidence that SKAP2 plays an important role in β-cells by regulating the sensitivity of the β-cells to cytokine-induced apoptosis.

RESEARCH DESIGN AND METHODS

Study Populations From the Hvidoere Study Group on Childhood Diabetes

The study population is described in Mortensen et al. (23). The cohort included 275 children (144 females), 84% White Caucasian, and age at clinical diagnosis was 9.1 years (range 0.2–16.8 years). The study was performed according to the criteria of the Helsinki II Declaration and was approved by the local ethics committee (permit number KA 04010gm) in each center as described in Mortensen et al. (23). Hba1c analysis was performed centrally by automatic high-pressure liquid chromatography at onset and 1, 3, 6, 9, and 12 months after diagnosis. A combined expression of insulin dose-adjusted Hba1c (IDAA1c) was used to define the partial remission period in children and adolescents with T1D (24). Genotyping of rs7804356 was done using the KASPar system (KBioscience), and typing of the HLA class II DRB1 locus was performed as described (23,25). The T1D-associated SNP rs7804356 located in the SKAP2 gene was tested for association with Hba1c and IDAA1c levels at 1, 3, 6, 9, and 12 months after diagnosis in linear regression models, assuming additive allelic effects for the risk allele (T). The regression models were adjusted for the covariates sex, age, and HLA risk group.

Human Pancreatic Islet Expression Quantitative Trait Loci Data

The human islet RNA-sequencing data set consisting of 118 individual islet preparations was downloaded from the European Genome-phenome Archive with accession number EGAS00001001265 (26). Bam files were analyzed for quality control using SAMtools (27). Gene, exon, CDS, and other genomic features were defined based on GRCh37 annotation (Ensembl v75). The fragments per kilobase of transcript per million mapped reads (FPKM) values were computed using Cufflinks v.2.2.1 (28). Islet-expressed genes were identified using a criterion of FPKM >1 in at least 10% of the samples.

Cell and Islet Culture

The INS-1E rat insulinoma cell line (29), provided by Claes Wollheim and Pierre Maechler (University of Geneva, Geneva, Switzerland), was maintained in RPMI medium with GlutaMAX supplemented with 10% heat-inactivated FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 50 μmol/L β-mercaptoethanol (all from Life Technologies). The human fusion 1.B4 cell line was obtained from Sigma-Aldrich and is a hybrid of primary human β-cells and the pancreatic ductal cell line PANC-1 (30). The cells were maintained as INS-1E cells but without β-mercaptoethanol. Isolation and culture of neonatal rat islets from Wistar rats (Taconic Biosciences, Eby, Denmark) were performed as previously described (31). Primary rat β-cells were FACs-purified (FACSaria; BD Biosciences) from isolated islets from male Wistar rats (Charles River Laboratories, Brussels, Belgium) as described (12). Isolated human islets from five organ donors without diabetes were purchased from Prodo Laboratories, Inc. via tebu-bio. Donor information is provided in the Supplementary Material. Human islets were maintained in F10 nutrient mix medium plus GlutaMAX and 10% FBS and penicillin/streptomycin. For experimentation, the same medium but with 2% human serum (Sigma-Aldrich) instead of FBS was used. B lymphoblastoid cell lines (BLCLs) from 55 HapMap Centre d’Etude du Polymorphism Humain/Utah founders were obtained from the Coriell Institute for Medical Research (https://catalog.coriell.org) and cultured as previously described (9). The following cell lines were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research: [GM06985, GM06993, GM06994, GM07000, GM07022, GM07055, GM07056, GM07345, GM07357, GM11829, GM11830, GM11831, GM11832, GM11839, GM11840, GM11881, GM11882, GM11992, GM11993, GM11994, GM11995, GM12003, GM12005, GM12006, GM12043, GM12044, GM12056, GM12057, GM12144, GM12145, GM12146, GM12154, GM12155, GM12156, GM12234, GM12239, GM12248, GM12249, GM12264, GM12750, GM12751, GM12760, GM12761, GM12762, GM12763, GM12812, GM12813, GM12814, GM12815, GM12872, GM12873, GM12874, GM12875, GM12891, GM12892]. All cells and islets were cultured at 37°C in a humidified atmosphere containing 5% CO2. Cells were seeded in duplicate or triplicate in appropriate dishes 2–3 days prior to experimentation. Recombinant mouse and human IL-1β were obtained from BD Phar- mingen and R&D Systems, respectively. Recombinant rat and human IFN-γ were from R&D Systems and PeproTech, respectively. Recombinant human tumor necrosis factor-α (TNF-α) was from R&D Systems. The concentrations and activities (in units per milliliter) of the cytokines and incubation times used for the cellular experiments depended on the exact cytokine batch and model system used and were chosen based on previous experience and optimizations for each of the models (9,10,14,31,32).

siRNA Transfection and Generation of Stable SKAP2-Overexpressing Clones

siGENOME SMARTpool siRNAs (Thermo Fisher Scientific) against rat and human SKAP2 were used. The final concentration of siRNA was 30 nmol/L. A pool of nontargeting siRNA (Thermo Fisher Scientific) or the AllStars Negative Control siRNA (Qiagen) was used as negative control. Cells were transfected using Lipofectamine RNAiMAX (Thermo
Fisher Scientific) as previously described (31,33). Clones of INS-1E cells overexpressing SKAP2 were generated using a mammalian expression plasmid (pcDNA3.1) encoding hemagglutinin (HA)–tagged mouse SKAP2 (HA–mSKAP2) provided by Dr. Landian Hu (34) using DharmaFECT 1 (Thermo Fisher Scientific) as transfection reagent. Stable SKAP2–overexpressing clones were established by adding G418 to the culture medium at 200 μg/mL for selection and 50 μg/mL for continuous culture of cells. Two clones of INS-1E cells that expressed HA–mSKAP2 (#A and #B) were selected for experimentation. A pool of INS-1E cells stably transfected with an empty plasmid (pcDNA3.1) only containing the neomycin selection gene was used as control cells. Transient transfection of INS-1E cells with the HA–mSKAP2 plasmid or the empty pcDNA3.1 control plasmid was done using the SF Cell Line 4D-Nucleofector X Kit S and a 4D-Nucleofector (both from Lonza Group Ltd.). After trypsinization, 2 × 10^6 cells were transferred to four Eppendorf tubes, which were then centrifuged at 200g for 5 min. The media was discarded, and 100 μL Nucleofector solution and 4 μg plasmid were added to each tube. The solution was then transferred to a Nucleocuvette, and cells were transfected using the Nucleofector program FF-150, according to the manufacturer’s recommendations. After transfection, the cells were seeded in appropriate cell culture dishes in RPMI medium supplemented with 10% FBS and 50 μmol/L β-mercaptoethanol (all from Life Technologies). The next day, the media was replaced with RPMI medium supplemented with 10% FBS, 50 μmol/L β-mercaptoethanol, 100 units/mL penicillin, and 100 μg/mL streptomycin (all from Life Technologies). The cells were incubated for another day before experimentation.

Gene Expression
RNA extraction, cDNA synthesis, and gene expression were performed either as previously described (9,33) or by using the miRNeasy Mini Kit spin columns (Qiagen) for RNA extraction, the iScript cDNA Synthesis Kit (Bio-Rad Laboratories), and TaqMan assays (Applied Biosystems) for real-time PCR analyses on a CFX384 C1000 Thermal Cycler (Bio-Rad Laboratories). Gene expression was normalized to Gapdh, Ppia, Hprt1, or the geometric mean of ACTB, GAPDH, and UBC. The relative expression levels were calculated from a standard curve or by the ΔΔ threshold cycle method and presented as fold change (mean ± SEM).

Apoptosis and Caspase 3/7 Activity
Apoptotic cell death was evaluated using either propidium iodide (PI) and Hoechst 33342 staining, as described previously (14), or by the detection of DNA–histone complexes (nucleosomes) present in the cytoplasmic fraction of cells using the Cell Death Detection ELISA PLUS assay (Roche), also as described previously (35). For measurement of caspase 3/7 activity, the Caspase-Glo 3/7 Assay (Promega) was used according to the manufacturer’s protocol. After measuring the caspase 3/7 activity, the CytoTox-Fluor assay measuring “cellular” protease activity was used to normalize the caspase 3/7 data.

Immunoblotting
Cells or islets were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) or in Laemmli buffer. Detergent-insoluble material was pelleted by centrifugation at 15,000g for 10 min at 4°C. The supernatants were stored at −80°C until further use. Protein concentration in cell lysate was determined by the Bradford method (Bio-Rad Laboratories). SDS-PAGE, preparation of nitrocellulose/polyvinylidene difluoride membranes, and immunoblotting were done as described previously (2,3,31). Primary antibodies used were: SKAP2 (#12926-1-AP; Proteintech Group), inducible nitric oxide synthase (iNOS) (#610332; BD Biosciences), cleaved caspase 3 (#9661; Cell Signaling Technology), CHOP (#sc-7351; Santa Cruz Biotechnology), phospho–nuclear factor-κB (NF-κB) p65 (#3033; Cell Signaling Technology), phospho-STAT1 (#7649; Cell Signaling Technology), β-actin (#ab6276; Abcam), α-tubulin (#T8203; Sigma-Aldrich), GAPDH (#ABS16; Millipore), Lamin A/C (#4C11; Cell Signaling Technology), and HA (#sc-805; Santa Cruz Biotechnology). Secondary horseradish peroxidase–conjugated antibodies were anti-rabbit IgG (#7074; Cell Signaling Technology), anti-mouse IgG (#7076; Cell Signaling Technology), and anti-goat IgG (#sc-2354; Santa Cruz Biotechnology). Immune complexes were visualized by chemiluminescence using LumiGLO (Cell Signaling Technology). Images were captured digitally on a Fujifilm LAS 4000, and quantitation was done by ImageQuant TL (GE Healthcare Life Sciences) software.

Statistics
Data are means ± SEM unless otherwise stated. For cellular and islet experiments, data were analyzed with ANOVA (GraphPad Prism) or Student t test (Excel) assuming equal variance, unless otherwise stated. Statistical analyses of clinical data were performed in SAS version 9.2 or R version 3.6. The expression quantitative trait loci (eQTL) effects were analyzed by ANOVA (GraphPad Prism). A P value ≤0.05 was considered statistically significant.

Data and Resource Availability
The data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. No applicable resources were generated or analyzed during the current study.

RESULTS
Rs7804356 in SKAP2 Predicts Glycemic Control in Patients With Newly Diagnosed T1D
To take previous genetic association studies a step further, we investigated if rs7804356 is associated with glycemic control the 1st year after diagnosis in a cohort consisting of 275 children with new-onset T1D (23). We found that
the C allele of rs7804356 was significantly associated with higher HbA1c (millimoles per mole and percentage) levels at 3, 6, 9, and 12 months after diagnosis, indicating poorer glycemic control (Fig. 1A and Supplementary Fig. 1). After removing the 16% non-Caucasians from the data, we still found a significant association between the C allele and higher HbA1c at 6 ($P = 0.047$) and 12 ($P = 0.012$) months and strong trends at 3 ($P = 0.057$) and 9 ($P = 0.062$) months. IDAA1c, which is an estimate of residual β-cell function (24), was also significantly increased in carriers of the C allele at 9 and 12 months after disease onset (Fig. 1B). These findings show that rs7804356 genotypes can predict glycemic control and residual β-cell function in the 1st year after T1D diagnosis and strengthen a possible causal role of SKAP2 in T1D.

**Rs7804356 Genotypes Affect SKAP2 Expression in Different Tissues**

A recent study showed that rs7804356 genotypes correlate with the SKAP2 expression level in immune cells (16). We confirmed an eQTL effect of rs7804356 on SKAP2 expression in Epstein-Barr virus–transformed BLCLs from the HapMap Consortium with lower SKAP2 expression in carriers of the T allele ($P = 0.0006$) (Fig. 1C). We then examined whether rs7804356 genotypes affect the expression level of SKAP2 in human pancreatic islets using publicly available data performed on 118 individual islet preparations (26). There were no significant differences in SKAP2 expression in human islets from donors carrying the different rs7804356 genotypes ($P = 0.3988$) (Fig. 1D). We next looked into possible eQTL effects of rs7804356 in other tissues as well using the public resource GTex Portal (https://gtexportal.org). We found an eQTL effect of the SNP on SKAP2 in whole blood, pancreas, lymphocytes, and fibroblasts (Supplementary Table 1). Interestingly, as seen in Supplementary Table 1, rs7804356 also had an eQTL effect on various nearby HOXA genes in blood and fibroblasts. Collectively, these results suggest that rs7804356 genotypes are associated with altered SKAP2 expression putatively in a tissue-specific manner.

**Proinflammatory Cytokines Modulate SKAP2 Expression**

We recently reported that exposure of human islets to proinflammatory cytokines for 48 h downregulates SKAP2 expression at the mRNA level (22). We further characterized SKAP2 expression and regulation by cytokine rat insulin-secreting INS-1E cells and isolated rat and human islets. In INS-1E cells, IL-1β plus IFN-γ suppressed SKAP2 both at the mRNA and protein levels after treatment for 24 h (Fig. 2A and B). In rat islets, IL-1β plus IFN-γ did not
affect the mRNA expression but caused a marked reduction in SKAP2 at the protein level after cytokine exposure (Fig. 2C and D). Extraction of RNA-sequencing data from a published study confirmed that a 24-h exposure to cytokines suppressed SKAP2 mRNA expression in human islets (Fig. 2E). At the protein level, cytokines downregulated SKAP2 in three out of five individual islet preparations following exposure to cytokines for 24 h (Fig. 2F and G).

**SKAP2 Has Antiapoptotic Activity in β-Cells**

We investigated if SKAP2 regulates β-cell apoptosis in response to cytokines by using an siRNA knockdown (KD) approach. Transfection of INS-1E cells with a pool of siRNAs targeting SKAP2 (siSKAP2) decreased SKAP2 expression by ~65% (Fig. 3A) and augmented both basal and cytokine-induced apoptosis (Fig. 3B), as compared with INS-1E cells transfected with a nontargeting negative
control siRNA (siCTRL). These results were verified by a significant increase in cytokine-induced caspase 3 cleavage in SKAP2-silenced INS-1E cells (Fig. 3C and D). In FACS-purified primary rat β-cells, KD of SKAP2 also caused an increase in the apoptosis rate, further demonstrating an antiapoptotic function of SKAP2 (Fig. 3E and F). Finally, experiments performed using the recently established human hybrid cell line 1.1B4 (30) also revealed increased cytokine-induced apoptosis following SKAP2 KD despite that cytokines modestly upregulated SKAP2 expression in these cells (Supplementary Fig. 1).

To further establish an antiapoptotic function of SKAP2 in β-cells, we generated two clones (referred to as #A and #B) of INS-1E cells with stable overexpression of HA-tagged SKAP2 (Fig. 4A). Cytokine-induced apoptosis was reduced in both SKAP2-overexpressing clones compared with INS-1E cells transfected with an empty vector (pcDNA) (Fig. 4B). These results were substantiated by the

Figure 3—Effects of SKAP2 KD on cytokine-induced apoptosis. A: INS-1E cells were transfected with siCTRL or siRNA against SKAP2 (siSKAP2). Cells were left untreated or exposed to cytokines (500 pg/mL human IL-1β plus 36 ng/mL rat IFN-γ) for 16 h. Skap2 mRNA expression was determined by real-time quantitative PCR and normalized to Gapdh. Data are presented as means ± SEM of n = 5. INS-1E cells transfected and treated as in A were subjected to measurement of apoptosis by Hoechst/PI staining (B) or immunoblotting of cleaved caspase (Casp) 3 (C and D). Data are means ± SEM of n = 4–5. Representative blots are shown. Purified primary rat β-cells were transfected as in A and left untreated or exposed to cytokines (2.5 ng/mL human IL-1β plus 72 ng/mL rat IFN-γ) for 24 h, after which Skap2 mRNA expression (E) and apoptosis (F) were determined by real-time quantitative PCR and Hoechst/PI staining, respectively. Skap2 expression was normalized to Gapdh. Data are means ± SEM of n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. siCTRL control (Ctrl); #P < 0.05; ##P < 0.01; ###P < 0.001.
observation that SKAP2 overexpression suppressed cytokine-induced caspase 3 cleavage (Fig. 4C and D). Interestingly, although clone #A and #B expressed different levels of HA-tagged SKAP2 (Fig. 4A), both clones were protected to a similar degree against the detrimental effects of the cytokines.

**SKAP2 Reduces iNOS Expression and Nuclear Phosphorylation of NF-κB p65**

An important event in cytokine signaling is the induction of iNOS, leading to generation of nitric oxide (NO), which contributes to β-cell apoptosis via endoplasmic reticulum (ER) stress and potentiation of cytokine signaling (37–39). We therefore examined if overexpression of SKAP2 affected cytokine-induced iNOS expression and NO production in INS-1E cells. Cytokine-induced NO production was decreased in the SKAP2-overexpressing clones (#A and #B) compared with the pcDNA control cells (Fig. 5A), which correlated with lower iNOS expression (Fig. 5B–D).

As NF-κB and STAT1 are the primary activators of iNOS expression in β-cells exposed to IL-1β and IFN-γ (40,41), we next investigated if SKAP2 modulates cytokine-induced...
Ser536 phosphorylation of NF-κB p65 (P-p65) and Tyr701 phosphorylation of STAT1 (P-STAT1) in INS-1E cells. For this purpose, we performed experiments on INS-1E cells transiently transfected to overexpress SKAP2 or an empty pcDNA vector to substantiate the results obtained using the individual clones. Efficient transient transfection was demonstrated by transfecting with a plasmid encoding GFP, which resulted in a transfection rate of 45% (Fig. 6A). As observed for the stable SKAP2-overexpressing clones, transient overexpression of SKAP2 decreased cytokine-induced apoptosis, as measured by reduced cytokine-mediated caspase 3 cleavage (Fig. 6B and C). Nuclear, but not cytosolic extracts from SKAP2-transfected INS-1E cells showed a marked reduction (49%) in P-p65 and a minor (17%) decrease in P-STAT1 compared with pcDNA-transfected control cells (Fig. 6D and E). These results suggest that SKAP2 dampens proximal signaling via NF-κB.

**SKAP2 Decreases Cytokine-Induced CHOP Expression**

Because NO contributes to cytokine-induced apoptosis by inducing ER stress (42), we next examined if SKAP2 modulates the expression of CHOP, a classical marker of ER stress (43), as would be anticipated based on the inhibitory effect on iNOS expression and NO formation. Comparison of the expression of CHOP between the SKAP2-overexpressing INS-1E cells and the pcDNA control cells in response to cytokine exposure revealed diminished IL-1β plus IFN-γ–induced CHOP protein expression in the SKAP2-overexpressing cells (Fig. 7A and B). Notably, as
opposed to overexpression, KD of SKAP2 did not modulate cytokine-induced CHOP expression (Fig. 7C). To determine the contribution of ER stress signaling via CHOP to SKAP2-dependent apoptosis regulation, we performed double-KD experiments in INS-1E cells in which SKAP2 and CHOP were silenced by siRNAs. Using this approach, it was observed that KD of CHOP abrogated the increase in cytokine-mediated apoptosis caused by KD of SKAP2 alone.

**Figure 6**—Effects of SKAP2 overexpression on phosphorylated p65–NF-κB and STAT1. A: INS-1E cells were transiently transfected with an expression plasmid encoding GFP to verify efficient transfection by microscopy. Nuclei staining was done by DAPI. B and C: INS-1E cells were transiently transfected with an empty vector (pcDNA) or a plasmid encoding HA-tagged SKAP2 before being left untreated or exposed to 150 pg/mL mouse IL-1β plus 5 ng/mL rat IFN-γ for 18 h. Lysates were subject to immunoblotting of HA-tagged SKAP2, cleaved caspase (Casp) 3, and GAPDH (C). Data are means ± SEM of n = 5. D and E: Cytosolic and nuclear extracts from INS-1E cells transfected and treated as in B for 60 min were prepared and subjected to immunoblotting of P-p65 and P-STAT1. Immunoblotting of Lamin A/C and GAPDH was used as cytosolic and nuclear markers, respectively. Total protein was stained by Ponceau. Representative blots are shown. Data are means ± SEM of n = 3–5. *P < 0.05 vs. pcDNA control (Ctrl); #P < 0.05.
Collectively, these results suggest that SKAP2 via regulatory effects on NF-κB and iNOS regulates cytokine-induced apoptosis in a CHOP-dependent manner. Interestingly, we also observed that apoptosis induced by thapsigargin, an inhibitor of the sarco- and ER calcium ATPase leading to ER calcium depletion and ER stress (44),
was significantly lower in SKAP2-overexpressing cells as compared with control cells (Supplementary Fig. 2).

**DISCUSSION**

In this study, we examined if the T1D candidate gene **SKAP2** has any functional roles in pancreatic β-cells relevant for the immune-mediated β-cell destruction observed in T1D. We show that the T1D-associated SNP rs7804356 in **SKAP2** is associated with glycemic control and residual β-cell function in the 1st year after diagnosis in children with new-onset T1D.

rs7804356 is located in the third intron of **SKAP2** and therefore does not affect the coding part of the gene. A recent study, however, demonstrated decreased **SKAP2** expression in B and T cells from patients with T1D carrying the T allele of rs7804356 (16), which we confirmed in HapMap BLCLs. The publicly available data on human islet eQTLs, which we used in this study, suggest that rs7804356 genotypes do not significantly modulate **SKAP2** expression in human pancreatic islets; however, if anything, the effect appears to be in the opposite direction (i.e., lowest **SKAP2** expression in carriers of the C allele of rs7804356). Considering that T is the risk allele, our finding is somewhat surprising and suggests complexity of how variation at the **SKAP2** locus affects disease risk in different tissues. Potentially, rs7804356 or other variants in the **SKAP2** locus may significantly affect **SKAP2** expression in islets under inflammatory conditions or in islets under direct immune attack preceding clinical T1D. Noteworthy, **SKAP2** could have a dual role by acting both in the target tissue (the β-cells) and the effector tissue (the immune cells) in T1D. These effects could be counterregulatory (i.e., whereas higher expression of **SKAP2** has a protective effect in β-cells, higher **SKAP2** expression in immune cells could cause a more aggressive immune attack against the β-cells). If true, this makes the involvement of **SKAP2** in T1D more complicated, but this may be what is reflected at the Hba1c/IDAA1c data for the rs7804356 genotypes. That lower **SKAP2** expression is associated with more fragile β-cells is supported by the observation that cytokines suppressed **SKAP2** at the protein level in INS-1E cells and rat islets and in most human islet preparations examined. The inconsistency observed in human islets, in which cytokines suppressed **SKAP2** at the protein level in three out of five islet preparations underlines the natural heterogeneity of human islets as compared with rodents. Unfortunately, we do not have genotype information on the human islets used in this study, but potentially this may have impacted the effects of cytokines on **SKAP2** protein expression.

Interestingly, the clinical data are supported by our in vitro data, which demonstrate an important apoptosis-regulatory role of **SKAP2** in β-cells. KD of **SKAP2** caused increased caspase activation and apoptosis in response to cytokines, whereas overexpression of **SKAP2** protected against the deleterious effects of cytokines in β-cells. The potentiating effect of silencing **SKAP2** on cytokine-induced apoptosis in INS-1E cells and primary rat β-cells together with the observed protective effect of overexpression of **SKAP2** on cytokine-induced apoptosis in INS-1E cells are, to the best of our knowledge, the first evidence that **SKAP2** possesses apoptosis-regulatory properties. Only limited information exists on the biological role of **SKAP2**. However, as mentioned, **SKAP2** interacts with actin and seems important for actin organization (20,21,34,45). In this regard, it is interesting to note that reorganization of actin filaments is correlated to apoptotic cell death (46). Thus, it should be investigated if the antiapoptotic activity of **SKAP2** is associated with an actin-regulatory effect in β-cells.

We found that the antiapoptotic effect of **SKAP2** was accompanied by lower levels of phosphorylated NF-κB p65 and STAT1 in the nucleus, possibly accounting for the diminished iNOS expression and NO production. This suggests that **SKAP2** regulates proximal cytokine signaling upstream of NF-κB and possibly also STAT1. This is conceivable with **SKAP2** being an Src kinase substrate thereby involved in proximal signal transduction (17). Src kinases or Src-related kinases, including YES and FRK, have previously been reported to be expressed and functionally important in β-cells and islets (47,48).

Our data also show that **SKAP2** overexpression correlates with lower CHOP induction following exposure to cytokines, suggesting reduced ER stress. Interestingly, our double-KD experiments revealed that the increased apoptosis level caused by KD of **SKAP2** alone was partly reversed by simultaneous KD of CHOP, indicating that ER stress signaling via CHOP is involved in **SKAP2**-regulated apoptosis. Whereas overexpression of **SKAP2** decreased cytokine-induced CHOP expression, KD of **SKAP2** failed to increase the cytokine-induced CHOP level in INS-1E cells. This could be due to the finding that cytokines downregulate **SKAP2** expression in the cells and further KD of **SKAP2** by siRNA is insufficient to further modulate cytokine-induced CHOP expression. The fact that we observed that **SKAP2** overexpression protected from both cytokine-induced and thapsigargin-induced apoptosis suggests that the antiapoptotic effect of **SKAP2** is not limited to controlling proximal cytokine signaling events, but also regulates apoptosis-promoting mechanisms operating at or above the ER stress level.

Cytokines suppressed the mRNA level of **SKAP2** in INS-1E cells and human islets, but not in rat islets. In contrast, cytokines downregulated **SKAP2** at the protein level in both INS-1E cells and rat islets, but not in human islets. These deviating observations could partly be due to species differences in sensitivity to cytokines and/or due to differences in the specific culturing and cytokine conditions and concentrations. However, it could also indicate that the regulation of **SKAP2** in β-cells/islets is highly complex and involves regulatory mechanisms acting posttranscriptionally yet to be defined. Such mechanisms could include noncoding RNAs, including micro RNAs. Indeed, cytokines modulate miRNA expression in β-cells (49), some of which could target **SKAP2** mRNA for translational inhibition.
However, further experiments are needed to clarify if miRNAs target SKAP2 in β-cells.

In conclusion, our study describes SKAP2 as a novel regulator of β-cell apoptosis. Prediction of the course of the residual β-cell function and glycemic control during disease progression in patients with T1D is important. The observation that rs7804356 in SKAP2 is associated with glycemic control and residual β-cell function in children with new-onset T1D suggests that this SNP can serve as a predictive marker of β-cell function in at-risk and recent-onset individuals.

Acknowledgment. The authors thank Anne Jørgensen, Ann-Sofie B. Hillese, and Tine Wille (Steno Diabetes Center Copenhagen, Gentofte, Denmark) for expert technical assistance.

Funding. Work by the group headed by J.S. was funded by the Det Frie Forskningsråd (Independent Research Fund Denmark; DFF-1331-00163A and DFF-7016-00282). Work in the group led by A.K.C. was supported by National Funds from Scientific Research (Fonds De La Recherche Scientifique Belgium; convention PDR T.0107.16) and the Excellence of Science grant (Fonds De La Recherche Scientifique Belgium; convention 30826052).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. L.B.N., A.K.C., and J.S. designed research. T.F., K.M., M.C.P., S.K., C.F., H.B.M., L.B.N., and J.S. researched data. T.F. and J.S. wrote the manuscript. All authors reviewed the manuscript and contributed with critical input to data interpretation and discussion. J.S. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented at the 54th annual European Association for the Study of Diabetes, Berlin, Germany, 1–5 October 2018.

References
1. Starling J, Overgaard AJ, Brorsson CA, et al. Do post-translational beta cell protein modifications trigger type 1 diabetes? Diabetologia 2013;56:2347–2354
2. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulin and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219–226
3. Groop L, Pociot F. Genetics of diabetes—does it matter? Nat Rev Endocrinol 2009;5:219–226
4. Pociot F, Lemmark Å. Genetic risk factors for type 1 diabetes. Lancet 2016; 387:2331–2339
5. Barrett JC, Clayton DG, Concannon P, et al.; Type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703–707
6. Onengut-Gumuscu S, Chen WM, Burren O, et al.; Type 1 Diabetes Genetics Consortium. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 2015; 47:381–386
7. Starling J, Pociot F. Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis. Genes (Basel) 2017;8:E72
8. Fleyel T, Kaur S, Pociot F. Genes affecting β-cell function in type 1 diabetes. Curr Diab Rep 2015;15:97
9. Fleyel T, Brorsson C, Nielsen LB, et al.; CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients. Proc Natl Acad Sci U S A 2014;111:10305–10310
10. Berchtold LA, Starling ZM, Ortis F, et al. Huntingtin-interacting protein 14 is a type 1 diabetes candidate protein regulating insulin secretion and beta-cell apoptosis. Proc Natl Acad Sci U S A 2011;108:E681–E688
11. Nogueira TC, Paula FM, Villate O, et al. GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim. PLoS Genet 2013;9:e1003532
12. Marroqui L, Dos Santos RS, Fleyel T, et al.; TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic β-cells. Diabetes 2015;64:3808–3817
13. Santin I, Moore F, Colli ML, et al.; PTEN, a candidate gene for type 1 diabetes, modulates pancreatic β-cell apoptosis via regulation of the BH3-only protein Bim. Diabetes 2011;60:3279–3288
14. Fukaya M, Brorsson CA, Meyerovich K, et al. A20 inhibits β-cell apoptosis by multiple mechanisms and predicts residual β-cell function in type 1 diabetes. Mol Endocrinol 2016;30:48–61
15. Bradfield JP, Qu H, Wang K, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet 2011;7:e1002293
16. Ram R, Mehta M, Nguyen QT, et al. Systematic evaluation of genes and genetic variants associated with type 1 diabetes susceptibility. J Immunol 2016;196:3043–3053
17. Marie-Caroline A, Verhagen AM, Eckersom C, Schraven B. SKAP-HOM, a novel adaptor protein homologous to the FYN-associated protein SKAP55. FEBS Lett 1998;435:55–60
18. Liu J, Kang H, Raab M, da Silva AJ, Kraeft SK, Rudd CE. FYB (FYN binding protein) serves as a binding partner for lymphoid protein and FYN kinase substrate SKAP55 and a SKAP55-related protein in T cells. Proc Natl Acad Sci U S A 1998;95:8779–8784
19. Togni M, Swanson KD, Reimann S, et al. Regulation of in vitro and in vivo immune functions by the cytosolic adaptor protein SKAP-HOM. Mol Cell Biol 2005; 25:8052–8063
20. Bourette RP, Thérier J, Mouchiroud G. Macrophage colony-stimulating factor receptor induces tyrosine phosphorylation of SKAP55R adaptor and its association with actin. Cell Signal 2005;17:941–949
21. Alenghat FJ, Baca OJ, Rubin NT, et al. Macrophages require Skap2 and Sirp α for integrin-stimulated cytoskeletal rearrangement. J Cell Sci 2012;125:5535–5545
22. Brorsson CA, Nielsen LB, Andersen ML, et al.; Hvidoeore Study Group on Childhood Diabetes. Genetic risk score modelling for disease progression in new-onset type 1 diabetes patients: increased genetic load of islet-expressed and cytokine-regulated candidate genes predicts poorer glycemic control. J Diabetes Res 2016;2016:9570424
23. Mortensen HB, Swift PG, Holl RW, et al.; Hvidoeore Study Group on Childhood Diabetes. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual β-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010;11:218–226
24. Mortensen HB, Hougaard P, Swift P, et al.; Hvidoeore Study Group on Childhood Diabetes. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32:1384–1390
25. Max Andersen ML, Hougaard P, Porksen S, et al. Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1c) in 129 Danish children with new-onset type 1 diabetes. Pediatr Diabetes 2014;15:469–476
26. van de Bunt M, Manning Fox JE, Dai X, et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet 2015;11:e1005694
27. Li H, Handsaker B, Wysoker A, et al.; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078–2079
28. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7:562–578
29. Mergler A, Theander S, Rubi B, Chaffard G, Wellheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 2004;145:667–678
30. McCluskey JT, Hamid M, Guo-Parkes H, McClennaghan NH, Gomis R, Flatt PR. Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrfusion. J Biol Chem 2011;286:21982–21992

31. Prause M, Berchtold LA, Urizar AI, et al. TRAF2 mediates JNK and STAT3 activation in response to IL-1β and IFNγ and facilitates apoptotic death of insulin-producing β-cells. Mol Cell Endocrinol 2016;420:24–36

32. Ortis F, Cardozo AK, Crispim D, Störling J, Mandrup-Poulsen T, Eizirik DL. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol Endocrinol 2006;20:1867–1879

33. Allagnat F, Fukaya M, Nogueira TC, et al. C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in β-cells. Cell Death Differ 2012;19:1836–1846

34. Zhou L, Zhang Z, Zheng Y, et al. SKAP2, a novel target of HSF4b, associates with NCK2/F-actin at membrane ruffles and regulates actin reorganization in lens cell. J Cell Mol Med 2011;15:783–795

35. Berchtold LA, Miani M, Diep TA, et al. Pannexin-2 deficiency sensitizes pancreatic β-cells to cytokine-induced apoptosis in vitro and impairs glucose tolerance in vivo. Mol Cell Endocrinol 2017;448:108–121

36. Elzirik DL, Sammeth M, Bouckennooge T, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012;8:e1002552

37. Oyadomari S, Takeda K, Takiguchi M, et al. Nitric oxide-induced apoptosis in pancreatic β-cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A 2001;98:10845–10850

38. Cardozo AK, Ortis F, Storling J, et al. Cytokines downregulate the sarcoplasmic reticulum Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes 2003;54:452–461

39. Starling J, Binzer J, Andersson AK, et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005;48:2039–2050

40. Cardozo AK, Heimberg H, Heremens Y, et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem 2001;276:48879–48886

41. Gysemans CA, Ladière L, Callewaert H, et al. Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes 2005;54:2396–2403

42. Berchtold LA, Prause M, Starling J, Mandrup-Poulsen T. Cytokines and pancreatic β-cell apoptosis. Adv Clin Chem 2016;75:99–158

43. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381–389

44. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 1991;266:17067–17071

45. Shimamura S, Sasaki K, Tanaka M. The Src substrate SKAP2 regulates actin assembly by interacting with WAVE2 and cortactin proteins. J Biol Chem 2013;288:1171–1183

46. Grzanka D, Gagat M, Izdebska M. Actin is required for cellular death. Acta Histochem 2013;115:775–782

47. Yoder SM, Dineen SL, Wang Z, Thurmond DC. YES, a Src family kinase, is a proximal glucose-specific activator of cell division cycle control protein 42 (Cdc42) in pancreatic islet β cells. J Biol Chem 2014;289:11476–11487

48. Welsh M, Welsh C, Ekman M, et al. The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. Biochem J 2004;382:261–268

49. Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic β-cells. Diabetes 2010;59:978–986